You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
The cost and value of cancer drugs – are new innovations outpacing our ability to pay?
|
|---|---|
| Published in |
Israel Journal of Health Policy Research, September 2016
|
| DOI | 10.1186/s13584-016-0097-0 |
| Pubmed ID | |
| Authors |
Daniel A. Goldstein, Salomon M. Stemmer, Noa Gordon |
| Abstract |
Cancer drug expenditures have been increasing significantly in countries around the world. A recent paper in the IJHPR provides new knowledge and insights into this global phenomenon by analyzing how it is playing out in an Israeli health plan with over two million members, whose state-of-the-art information systems provide an opportunity to explore these changes in a comprehensive, detailed and reliable manner. There is a wide variation in both the cost-effectiveness and the budget impact of individual drugs. These issues also vary when analyzing drugs in other countries due to differential pricing mechanisms. In addition to drug expenditure, the overall cost of cancer care is increasing, partly due to expenditures on non-pharmacologic treatments and diagnostic testing. With the arrival of new therapies, the future of cancer care is exciting. However, there will be many challenges ahead with regard to the ability to pay for such innovations. In this commentary we discuss the current problems and anticipate the future challenges. |
Mendeley readers
The data shown below were compiled from readership statistics for 49 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 49 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 10 | 20% |
| Student > Master | 8 | 16% |
| Student > Ph. D. Student | 6 | 12% |
| Student > Doctoral Student | 4 | 8% |
| Student > Bachelor | 3 | 6% |
| Other | 6 | 12% |
| Unknown | 12 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 10 | 20% |
| Economics, Econometrics and Finance | 8 | 16% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 8% |
| Engineering | 3 | 6% |
| Nursing and Health Professions | 2 | 4% |
| Other | 8 | 16% |
| Unknown | 14 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 36. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 September 2017.
All research outputs
#953,112
of 23,001,641 outputs
Outputs from Israel Journal of Health Policy Research
#11
of 580 outputs
Outputs of similar age
#19,111
of 321,571 outputs
Outputs of similar age from Israel Journal of Health Policy Research
#1
of 7 outputs
Altmetric has tracked 23,001,641 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 580 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.5. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 321,571 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them